Long term results and complications of trabeculectomy augmented with low dose mitomycin C in patients at risk for filtration failure

AIM To determine the results and complications up to 5 years after trabeculectomy with 0.02% mitomycin C (MMC) in glaucoma patients at risk for failure of filtration surgery. METHODS A consecutive series of 21 eyes from 20 patients who underwent trabeculectomy with MMC 0.02%, with an exposure time of 2 minutes, was retrospectively analysed and the results were compared with previously published data. RESULTS The mean preoperative intraocular pressure (IOP) was 28 mm Hg on an average of 2.8 glaucoma medications, and the mean postoperative IOP after 3 years was 14 mm Hg on an average of 0.4 medications. Three years after trabeculectomy, 17 of 21 (80.9%) eyes had an IOP of less than 21 mm Hg without medical treatment. Using Kaplan-Meier life table analysis the 5 year probability of an IOP less than 21 mm Hg without medication was 67% and with medication was 90%. Two patients required further glaucoma surgery during the first postoperative year, and another developed hypotonous maculopathy which was reversed after bleb revision. Seven patients developed visually significant cataract as a late consequence of the surgery. There were no bleb related infections. CONCLUSION In the long term MMC 0.02% used for 2 minutes intraoperatively is an effective adjunctive treatment in glaucoma patients at risk for bleb failure and in this dose is associated with few complications.

[1]  Tetsuya Yamamoto,et al.  The effect of mitomycin C trabeculectomy on the progression of visual field defect in normal-tension glaucoma , 2000, Graefe's Archive for Clinical and Experimental Ophthalmology.

[2]  N. Occleston,et al.  Sponge delivery variables and tissue levels of 5-fluorouracil , 2000, The British journal of ophthalmology.

[3]  G. Krieglstein,et al.  Adjunctive mitomycin C in primary trabeculectomy in young adults: a long-term study of case-matched young patients , 1998, Graefe's Archive for Clinical and Experimental Ophthalmology.

[4]  P. Kaufman,et al.  Trabeculectomy with mitomycin C: intermediate-term results. , 1998, Journal of glaucoma.

[5]  S. Beatty,et al.  Trabeculectomy augmented with mitomycin C application under the scleral flap , 1998, The British journal of ophthalmology.

[6]  L. Herndon,et al.  Results of Trabeculectomy with 0.3 mg/ml Mitomycin C Titrating Exposure Times Based on Risk Factors for Failure , 1998, Journal of glaucoma.

[7]  R. Parrish,et al.  Use of antifibrosis agents and glaucoma drainage devices in the American and Japanese Glaucoma Societies. , 1997, Journal of glaucoma.

[8]  M. F. Smith,et al.  Results of Intraoperative 5‐Fluorouracil or Lower Dose Mitomycin‐C Administration on Initial Trabeculectomy Surgery , 1997, Journal of glaucoma.

[9]  J. Pederson,et al.  Intermediate-term outcome of variable dose mitomycin C filtering surgery. , 1997, Ophthalmology.

[10]  H. Flynn,et al.  Endophthalmitis after filtering surgery with mitomycin. , 1996, Archives of ophthalmology.

[11]  R. D'Amato,et al.  Angiogenesis inhibition in age-related macular degeneration. , 1995, Ophthalmology.

[12]  J. G. Ford,et al.  Central visual field changes associated with acquired pits of the optic nerve. , 1995, Ophthalmology.

[13]  D. Minckler,et al.  Postoperative Complications and Short‐Term Outcome After 5‐Fluorouracil or Mitomycin‐C Trabeculectomy , 1995, Journal of glaucoma.

[14]  P. Lichter,et al.  Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery. Extended follow-up. , 1995, Ophthalmology.

[15]  K. Lamping,et al.  5-Fluorouracil and mitomycin C in pseudophakic patients. , 1995, Ophthalmology.

[16]  J. Salmon,et al.  The effect of reducing the exposure time of mitomycin C in glaucoma filtering surgery. , 1995, Ophthalmology.

[17]  C. O'brien,et al.  Success rate and complications of intraoperative 0.2 mg/ml Mitomycin C in trabeculectomy surgery , 1995, Eye.

[18]  M. B. Shields,et al.  Clinical and histopathologic observations concerning hypotony after trabeculectomy with adjunctive mitomycin C. , 1993, American journal of ophthalmology.

[19]  V. P. Costa,et al.  Effects of topical mitomycin C on primary trabeculectomies and combined procedures. , 1993, The British journal of ophthalmology.

[20]  J. Schuman,et al.  Ocular hypotony after trabeculectomy with mitomycin C. , 1993, American journal of ophthalmology.

[21]  H. Jampel Effect of brief exposure to mitomycin C on viability and proliferation of cultured human Tenon's capsule fibroblasts. , 1992, Ophthalmology.

[22]  P. Lichter,et al.  Intraoperative mitomycin versus postoperative 5-fluorouracil in high-risk glaucoma filtering surgery. , 1992, Ophthalmology.

[23]  Y. Kitazawa,et al.  Trabeculectomy with mitomycin. A comparative study with fluorouracil. , 1991, Archives of ophthalmology.

[24]  S. Palmer,et al.  Mitomycin as adjunct chemotherapy with trabeculectomy. , 1991, Ophthalmology.

[25]  C. W. Chen,et al.  Trabeculectomy with simultaneous topical application of mitomycin-C in refractory glaucoma. , 1990, Journal of ocular pharmacology.